Gregory Brooks Bass Net Worth

The estimated Net Worth of Gregory Brooks Bass is at least $36.8 Thousand dollars as of 29 December 2017. Gregory Bass owns over 9,375 units of Lipocine Inc stock worth over $36,750 and over the last 7 years Gregory sold LPCN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Gregory Bass LPCN stock SEC Form 4 insiders trading

Gregory has made over 1 trades of the Lipocine Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Gregory exercised 9,375 units of LPCN stock worth $36,750 on 29 December 2017.

The largest trade Gregory's ever made was exercising 9,375 units of Lipocine Inc stock on 29 December 2017 worth over $36,750. On average, Gregory trades about 4,688 units every 0 days since 2017. As of 29 December 2017 Gregory still owns at least 9,375 units of Lipocine Inc stock.

You can see the complete history of Gregory Bass stock trades at the bottom of the page.

What's Gregory Bass's mailing address?

Gregory's mailing address filed with the SEC is 675 ARAPEEN DRIVE, SUITE 202, 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT, 84010.

Insiders trading at Lipocine Inc

Over the last 11 years, insiders at Lipocine Inc have traded over $9,045 worth of Lipocine Inc stock and bought 890,945 units worth $696,169 . The most active insiders traders include Mahesh V. Patel, John W. Higuchi, and Morgan R Brown. On average, Lipocine Inc executives and independent directors trade stock every 72 days with the average trade being worth of $148,846. The most recent stock trade was executed by Mahesh V. Patel on 25 May 2023, trading 8,706 units of LPCN stock currently worth $43,791.

What does Lipocine Inc do?

lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.

Complete history of Gregory Bass stock trades at Lipocine Inc

Lipocine Inc executives and stock owners

Lipocine Inc executives and other stock owners filed with the SEC include:

• Mahesh Patel,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Mahesh V. Patel Ph.D.,
  Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO
• Dr. Mahesh V. Patel,
  Co-Founder, Chairman, Pres & CEO
• Morgan R. Brown CPA, CPA, M.B.A., MBA,
  Corp. Sec.
• Morgan R. Brown CPA, M.B.A., CPA, MBA,
  Exec. VP, CFO, Principal Accounting Officer & Corp. Sec.
• Morgan Brown,
  Chief Financial Officer, Executive Vice President
• Nachiappan Chidambaram Ph.D.,
  VP of Product Devel.
• John Higuchi,
  Non-Executive Director
• Richard Ono,
  Director
• Jeffrey Fink,
  Director
• Stephen Hill,
  Lead Independent Director
• Krista Fogarty,
  Principal Accounting Officer & Corp. Controller
• Dr. Anthony DelConte M.D., M. D.,
  Chief Medical Director
• Logan Morse,
  VP of Sales, Marketing & Operations
• Jyrki Mattila,
  Chief Business Officer
• Gregory Brooks Bass,
  EVP and Chief Commercial Offic
• Srinivasan Venkateshwaran,
  CTO and VP RandD
• Gerald T Simmons,
  VP Corp Business Development
• Robert K. Merrell,
  VP Finance
• Jill M. Jene,
  Director
• Spyros Papapetropoulos,
  Director
• Krista Fogarty,
  Principal Accounting Officer
• George Nomikos,
  Chief Medical Officer